Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 70 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Post-Herpetic Neuralgia (PHN) Clear all
Not listed Phase 2 Interventional

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

NCT00652184
View directory record Official record
Conditions
Herpes Zoster, Postherpetic Neuralgia
Interventions
ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir
Drug
Lead sponsor
aRigen Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Beverly Hills, California • Encino, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01129531
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
AGN-214868, Placebo to AGN-214868
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2013 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Not applicable Interventional

Reduction of Postherpetic Neuralgia in Herpes Zoster

NCT01250561
View directory record Official record
Conditions
Herpes Zoster, Post-herpetic Neuralgia
Interventions
Gabapentin, Valacyclovir
Drug
Lead sponsor
Center for Clinical Studies, Texas
Other
Eligibility
50 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Sep 30, 2026, 6:13 PM EDT
Terminated Phase 3 Interventional

A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia

NCT02412917
View directory record Official record
Conditions
Shingles, Herpes Zoster, Postherpetic Neuralgia
Interventions
FV-100, valacyclovir
Drug
Lead sponsor
ContraVir Pharmaceuticals, Inc.
Industry
Eligibility
30 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia

NCT01757873
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Z160, Placebo
Drug
Lead sponsor
Zalicus
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
53
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)

NCT00576108
View directory record Official record
Conditions
Postherpetic Neuralgia, Shingles, Herpes Zoster, Neuropathic Pain
Interventions
KD7040 Topical Gel, Placebo gel
Drug
Lead sponsor
Kalypsys, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 22, 2008 · Synced Sep 30, 2026, 6:13 PM EDT
Active, not recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Chronic Neuropathic Pain

NCT05593237
View directory record Official record
Conditions
Chronic Neuropathic Pain, Post-Stroke Pain, Trigeminal Neuralgia, Nerve Injury, Spinal Cord Injuries, Pain, Postoperative, Complex Regional Pain Syndromes, Post-herpetic Neuralgia, Nerve Root Avulsion
Interventions
High Frequency rTMS, Low Frequency rTMS
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Safety and Analgesic Activity of ATx08-001 in Subjects With Postherpetic Neuralgia

NCT01318226
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
ATx08-001, Placebo
Drug
Lead sponsor
Aestus Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
9
States / cities
Chandler, Arizona • Peoria, Arizona • Cutler Bay (Miami), Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Topical Treatment for Continued Pain After Shingles

NCT00566904
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Epikeia coatings with aspirin, Epikeia coatings with lidocaine, Epikeia coatings alone
Drug · Other
Lead sponsor
Biomedical Development Corporation
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2011 · Synced Sep 30, 2026, 6:13 PM EDT
Terminated Phase 2 Interventional

A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.

NCT00353808
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
57
States / cities
Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2011 · Synced Sep 30, 2026, 6:13 PM EDT
Not yet recruiting Phase 1 Interventional

Simultaneous Engagement of Networks for Alleviating Pain (SENAP)

NCT07057206
View directory record Official record
Conditions
Neuropathic Pain, Postherpetic Neuralgia
Interventions
PFM-guided cortical stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

NCT04662281
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Placebo, LX9211
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Greenbrae, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluating E2007 (Perampanel) in Patients With Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN)

NCT00592904
View directory record Official record
Conditions
Neuralgia
Interventions
E2007
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 30, 2026, 6:13 PM EDT
Terminated Phase 2 Interventional Results available

Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve

NCT01886313
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
Civamide Nasal Spray, Placebo
Drug
Lead sponsor
Winston Laboratories
Industry
Eligibility
21 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Santa Monica, California • Lauderdale Lakes, Florida • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Sep 30, 2026, 6:13 PM EDT
Not listed Phase 2 Interventional

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

NCT00813826
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
SLC022, Placebo
Drug
Lead sponsor
Solace Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional Results available

RN624 For Pain Of Post-Herpetic Neuralgia

NCT00568321
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
RN624, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
31
States / cities
Anniston, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Sep 30, 2026, 6:13 PM EDT
Terminated Phase 2Phase 3 Interventional

Lamictal in the Treatment of Post-Herpetic Neuralgia

NCT00295776
View directory record Official record
Conditions
Neuralgia, Postherpetic
Interventions
Lamictal in the treatment of Post-Herpetic Neuralgia
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 85 Years
Timeline
Started 2005
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

NCT00609323
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
lidocaine and tetracaine cream 7%/7%, Placebo
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Lexington, Kentucky • High Point, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2012 · Synced Sep 30, 2026, 6:13 PM EDT
Terminated Phase 2 Interventional

[S,S]-Reboxetine Long Term Safety Study In Post-Shingles Pain.

NCT00354094
View directory record Official record
Conditions
Pain
Interventions
[S,S]-Reboxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
6
States / cities
Tampa, Florida • West Palm Beach, Florida • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Sep 30, 2026, 6:13 PM EDT
Recruiting Not applicable Interventional

Closed-Loop Deep Brain Stimulation for Refractory Chronic Pain

NCT04144972
View directory record Official record
Conditions
Spinal Cord Injuries, Nerve Injury, Pain, Postoperative, Post Herpetic Neuralgia, Complex Regional Pain Syndromes, Post-Stroke Pain, Post Radiation Brain Injury, Post Radiation Plexopathy, Nerve Root Avulsion
Interventions
Medtronic Summit RC+S or Percept RC
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

NCT01228838
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
NGX-1998, Placebo Liquid
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Huntsville, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 30, 2026, 6:13 PM EDT
Completed Phase 2 Interventional

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

NCT00916942
View directory record Official record
Conditions
Postherpetic Neuralgia
Interventions
capsaicin 8%, Lidocaine (2.5%)/Prilocaine (2.5%) Cream
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
6
States / cities
Naples, Florida • St. Petersburg, Florida • Marietta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2009 · Synced Sep 30, 2026, 6:13 PM EDT